Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Countries: Sweden Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Long ‐term excess risk of stroke in people with Type 2 diabetes in Sweden according to blood pressure level: a population‐based case–control study
ConclusionsPeople with Type 2 diabetes and blood pressure < 130/80 mmHg had a risk of stroke similar to that of the general population.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - November 24, 2016 Category: Endocrinology Authors: C. H. Stahl, M. Lind, A. ‐M. Svensson, M. Kosiborod, S. Gudbjörnsdottir, A. Pivodic, M. Clements, A. Rosengren Tags: Original Article Source Type: research
Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
ConclusionsASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.
Source: Diabetes Therapy - June 16, 2023 Category: Endocrinology Source Type: research
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research
Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden.
CONCLUSIONS: We have found evidence that patients with type 1 diabetes in Sweden with prior severe hypoglycemic events have increased risk of mortality after a cardiovascular event.
PMID: 25092684 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 4, 2014 Category: Endocrinology Authors: Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, Clarke PM Tags: Diabetes Care Source Type: research
Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research
Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
Publication date: Available online 5 December 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Henrik Svanström, Peter Ueda, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn PasternakSummaryBackgroundTrial evidence shows that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major cardiovascular events among patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk. We aimed to assess the cardiovascular effectiveness of liraglutide in rou...
Source: The Lancet Diabetes and Endocrinology - December 6, 2018 Category: Endocrinology Source Type: research
Editorial: Telomeres and Epigenetics in Endocrinology
This study was hypothesis-driven; the genetic variants were selected for being previously and substantially genotyped. The big sample size and the rich panel of other biomarkers allowed the authors to conduct much more detailed analyses on this topic.
The third article by Provenzi et al. proposed their perspectives on the role of telomeres in premature birth and discussed the potential implications for early adversity and care in the neonatal intensive care unit (Pavanello et al.). Indeed, the speculation of telomeres in aging begins in the premature aging syndrome. It is thus interesting to examine if telomeres also play...
Source: Frontiers in Endocrinology - April 23, 2019 Category: Endocrinology Source Type: research
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research
Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research
